Study | SCD operationalization criteria | |||
---|---|---|---|---|
Criterion 1 Endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment | + Criterion 2 Intact functional ability | + Criterion 3 No major depression | + Criterion 4 No anxiety disorder | |
Prevalence estimates in % (95%CI) | ||||
ActiveAging | 27.97 (21.43–34.51) | 25.80 (19.40–32.20) | 25.73 (19.36–32.10) | N/A |
CFAS | 23.44 (21.77–25.12) | 21.59 (19.91–23.26) | 17.78 (16.36–19.20) | 9.60 (8.63–10.58) |
EAS | 50.41 (45.20–55.62) | 46.06 (41.06–51.06) | 38.71 (34.07–43.34) | 25.91 (19.33–32.48) |
EPIDEMCA | 56.28 (54.18–58.38) | 53.02 (50.83–55.21) | 30.64 (28.51–32.77) | 28.41 (26.38–30.44) |
ESPRIT | 31.26 (29.34–33.18) | 28.76 (26.89–30.63) | 23.97 (22.20–25.74) | 18.94 (17.36–20.51) |
Invece.Ab | 14.61 (11.64–17.58) | 14.03 (10.90–17.17) | 12.32 (9.44–15.20) | 10.77 (8.28–13.26) |
KLOSCAD | 55.51 (54.09–56.92) | 50.55 (49.10–52.00) | 36.01 (34.62–37.40) | 35.97 (34.62–37.31) |
LEILA75+ | 12.89 (11.66–14.13) | 11.71 (10.49–12.94) | 9.81 (8.65–10.97) | N/A |
LRGS-TUA | 51.23 (48.15–54.31) | 47.40 (44.32–50.47) | 46.84 (43.80–49.87) | N/A |
MAAS | 65.26 (60.32–70.20) | 60.52 (55.34–65.69) | 54.97 (49.43–60.51) | 52.70 (47.43–57.98) |
MoVIES | 29.39 (26.97–31.81) | 27.20 (24.83–29.57) | 23.87 (21.59–26.15) | N/A |
PATH | 11.68 (10.50–12.86) | 10.76 (9.62–11.90) | 9.63 (8.54–10.73) | 7.83 (6.80–8.87) |
SGS | 18.47 (16.81–20.12) | 16.51 (14.93–18.09) | 10.24 (8.93–11.54) | 9.91 (8.64–11.18) |
SLASII | 25.48 (23.37–27.59) | 22.87 (20.83–24.91) | 22.17 (20.16–24.18) | 21.18 (19.31–23.05) |
SydneyMAS | 45.81 (43.41–46.39) | 42.72 (40.48–44.95) | 35.87 (33.55–38.19) | 29.88 (27.54–32.22) |
ZARADEMP | 44.69 (42.99–46.39) | 42.04 (40.32–43.77) | 30.64 (28.51–32.77) | 28.12 (26.50–29.74) |
Total* | 37.32 (36.85–37.79) | 34.49 (34.02–34.97) | 27.75 (27.31–28.20) | 25.60 (25.06–26.14) |